Evidence map›Paper›PMID 26673167›Full record

ArticlePloS one2015

Tongxinluo Protects against Hypertensive Kidney Injury in Spontaneously-Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead Box O1 Signaling.

Wei-Min Luo, Jing Kong, Yan Gong, Xiao-Qiong Liu, Rui-Xue Yang, Yu-Xia Zhao

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wei-Min LuoKey Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Jing KongKey Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Yan GongDepartment of Magnetic Resonance Imaging, Jinan hospital of infectious diseases, Jinan, Shandong, China.
Xiao-Qiong LiuDepartment of Cardiology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Rui-Xue YangDepartment of Cardiology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Yu-Xia ZhaoDepartment of Traditional Chinese Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Qilu Hospital of Shandong University · CNShandong University · CNJinan Infectious Disease Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension is an independent risk factor for the progression of chronic renal failure, and oxidative stress plays a critical role in hypertensive renal damage. Forkbox O1(FoxO1) signaling protects cells against oxidative stress and may be a useful target for treating oxidative stress-induced hypertension. Tongxinluo is a traditional Chinese medicine with cardioprotective and renoprotective functions. Therefore, this study aimed to determine the effects of Tongxinluo in hypertensive renal damage in spontaneously hypertensive rats(SHRs)and elucidate the possible involvement of oxidative stress and FoxO1 signaling in its molecular mechanisms. SHRs treated with Tongxinluo for 12 weeks showed a reduction in systolic blood pressure. In addition to increasing creatinine clearance, Tongxinluo decreased urinary albumin excretion, oxidative stress injury markers including malondialdehyde and protein carbonyls, and expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and its activity in SHR kidneys. While decreasing phosphorylation of FoxO1, Tongxinluo also inhibited the phosphorylation of extracellular signal-regulated kinase1/2 and p38 and enhanced manganese superoxide dismutase and catalase activities in SHR kidneys. Furthermore, histology revealed attenuation of glomerulosclerosis and renal podocyte injury, while Tongxinluo decreased the expression of α-smooth muscle actin, extracellular matrixprotein, transforming growth factor β1 and small mothers against decapentaplegic homolog 3,and improved tubulointerstitial fibrosis in SHR kidneys. Finally, Tongxinluo inhibited inflammatory cell infiltration as well as expression of tumor necrosis factor-α and interleukin-6. In conclusion, Tongxinluo protected SHRs against hypertension-induced renal injury by exerting antioxidant, antifibrotic, and anti-inflammatory activities. Moreover, the underlying mechanisms of these effects may involve inhibition of oxidative stress and functional activation of FoxO1 signaling.

Indexed as

Oxidative StressAnimalsAntioxidantsCatalaseCytokinesDrugs, Chinese HerbalForkhead Box Protein O1Forkhead Transcription FactorsHypertension, RenalMaleMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nerve Tissue Proteinsp38 Mitogen-Activated Protein KinasesProteinuriaRatsAntioxidantsCatalaseCytokinesDrugs, Chinese HerbalForkhead Box Protein O1Forkhead Transcription FactorsFoxo1 protein, ratMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nerve Tissue Proteinsp38 Mitogen-Activated Protein KinasesSuperoxide Dismutasetongxinluo

Identifiers

PMID26673167
PMCPMC4686063
OpenAlexW2209661158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.